ClearB Therapeutics 宣布即将在 AASLD 2022 上发布临床前乙型肝炎数

StephenW

ClearB Therapeutics 宣布即将在 AASLD 2022 上发布临床前乙型肝炎数据的海报展示
东部夏令时间 2022 年 10 月 24 日下午 12:50

马萨诸塞州康科德--(BUSINESS WIRE)--(美国商业资讯)--ClearB Therapeutics, Inc. 是一家开发 CLB-3000 的公司，该公司开发了一种治疗性疫苗，旨在推动慢性乙型肝炎感染患者的功能性治愈，该公司今天宣布，两篇摘要被接受为海报2022 年 11 月 4 日至 8 日在美国华盛顿特区举行的美国肝病研究协会 (AASLD) 肝脏会议上的演讲。

    “我们很高兴继续让乙型肝炎社区了解我们在候选治疗性疫苗 CLB-3000 方面取得的进展，在人体试验中取得第一个进展，以及我们对这种新颖和差异化方法的信心”
    发推文

“我们很高兴继续让乙型肝炎社区了解我们在候选治疗性疫苗 CLB-3000 方面取得的进展，在人体试验中取得首个进展，以及我们对这种新颖和差异化方法的信心，”该公司首席执行官 Aileen Rubio 博士说。公司。慢性乙型肝炎 (CHB) 感染仍然是影响数亿人的重要全球疾病，其中功能性治愈仍然难以捉摸，可能需要联合治疗。我们相信，通过施用 ClearB 的治疗性疫苗对患者的免疫系统进行再教育以打破对慢性 HBV 感染的耐受性可能成为联合治疗方案的重要组成部分。”

摘要编号/海报编号：36528 / SAT1193
摘要标题：乙型肝炎治疗候选疫苗 CLB-3000（CLB-405 + CLB-505 与 Alhydrogel）的评估：在新西兰白 (NZW) 兔中进行的 9 或 15 周毒性研究，恢复期为 4 周
日期：2022 年 11 月 4 日，星期五
时间：美国东部时间下午 12:00
演讲者姓名：Aileen Rubio，ClearB Therapeutics

摘要编号/海报编号：37190 / SAT1215
摘要标题 : 在新西兰白兔 (NZW) 中使用或不使用 Alhydrogel 的重组乙型肝炎表面抗原 (HBsAg) 变体 CLB-405 和 CLB-505 的剂量水平增加肌肉内接种后的免疫原性
日期：2022 年 11 月 4 日，星期五
时间：美国东部时间下午 12:00
演讲者姓名：Aileen Rubio，ClearB Therapeutics

有关 AASLD 2022 的更多信息，请访问
肝脏会议 | AASLD

关于 ClearB Therapeutics
ClearB Therapeutics 由 Morningside Ventures 与 Stephen Locarnini 教授和澳大利亚墨尔本的维多利亚传染病参考实验室于 2017 年共同创立。 ClearB 正致力于开发旨在推动乙型肝炎功能性治愈的治疗性疫苗。这项工作的基础是从研究慢性乙型肝炎患者的罕见感染解决方案中获得的专有见解。有关更多信息，请访问 https:// clearbtherapeutics.com/。

StephenW

ClearB Therapeutics Announces Upcoming Poster Presentations of Pre-Clinical Hepatitis B Data at AASLD 2022
October 24, 2022 12:50 PM Eastern Daylight Time

CONCORD, Mass.--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure in patients chronically infected with Hepatitis B, announced today that two abstracts were accepted for poster presentation at the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting, to be held in Washington, DC, USA, November 4 – 8, 2022.

    “We are excited to continue to make the Hepatitis B community aware of our progress for the therapeutic vaccine candidate CLB-3000, toward first in human trials and our confidence in this novel and differentiated approach”
    Tweet this

“We are excited to continue to make the Hepatitis B community aware of our progress for the therapeutic vaccine candidate CLB-3000, toward first in human trials and our confidence in this novel and differentiated approach” said Aileen Rubio, PhD., CEO for the company. Chronic infection with Hepatitis B (CHB) remains a significant global disease infecting hundreds of millions of people, where functional cure remains elusive and combination therapies are likely needed. We believe that re-education of patients’ immune systems to break tolerance of their chronic HBV infections through administration of ClearB’s therapeutic vaccine could become an important component of combination treatment regimens.”

Abstract Number / Poster Number: 36528 / SAT1193
Abstract Title : Evaluation of the Hepatitis B therapeutic vaccine candidate CLB-3000 (CLB-405 + CLB-505 with Alhydrogel): a 9- or 15-week toxicity study in New Zealand White (NZW) rabbits with a 4-week recovery period
Date: Friday, 4 November 2022
Time: 12:00 pm EDT
Presenter Name: Aileen Rubio, ClearB Therapeutics

Abstract Number / Poster Number: 37190 / SAT1215
Abstract Title : Immunogenicity following intramuscular vaccination with increasing dose levels of recombinant Hepatitis B surface antigen (HBsAg) variants CLB-405 and CLB-505 with or without Alhydrogel in New Zealand White (NZW) rabbits
Date: Friday, 4 November 2022
Time: 12:00 pm EDT
Presenter Name: Aileen Rubio, ClearB Therapeutics

For more information regarding AASLD 2022 please visit
The Liver Meeting | AASLD

About ClearB Therapeutics
ClearB Therapeutics was co-founded in 2017 by Morningside Ventures in collaboration with Professor Stephen Locarnini and the Victoria Infectious Diseases Reference Laboratory in Melbourne, Australia. ClearB is working to develop therapeutic vaccines designed to drive functional cure of Hepatitis B. The work is grounded in proprietary insights derived from studying rare-event infection resolution in patients who suffer from chronic Hepatitis B. For more information, please visit https://clearbtherapeutics.com/.